Estrone (E1) Lab Results: Normal Reference Ranges vs. Functional Optimal Levels

What Is Estrone and Why It Matters

Estrone is the weakest of the three endogenous estrogens (E1, E2, E3), yet it becomes the most abundant one circulating after menopause. While estradiol (E2) dominates during reproductive years, the ovaries produce far less of it once follicular activity ceases. Adipose tissue picks up the slack by converting adrenal androstenedione into estrone via the aromatase enzyme [1].

This shift matters for two reasons. First, estrone's biological activity is roughly one-tenth that of estradiol at the estrogen receptor, which means that even "normal" E1 levels may not protect bone, brain, or cardiovascular tissue the way premenopausal estradiol once did [2]. Second, estrone can be converted to estrone sulfate (E1S), a long-lived storage form that acts as a reservoir. E1S circulates at concentrations 10 to 20 times higher than unconjugated E1 and can be reactivated in target tissues, including breast tissue [3]. A 2019 analysis in the Journal of Clinical Endocrinology & Metabolism found that women in the highest quartile of circulating E1S had a 1.8-fold increased risk of postmenopausal breast cancer compared to those in the lowest quartile [4].

Understanding your estrone level in context, not just whether the lab flags it as "H" or "L," is the foundation of informed hormone management.

Standard Reference Ranges: What Labs Report

Most commercial laboratories define "normal" estrone ranges by measuring levels in a large reference population and marking the central 95th percentile. The result is a wide band that reflects statistical distribution, not clinical optimization.

Typical reported ranges look like this. Premenopausal women in the follicular phase: 17 to 200 pg/mL. Premenopausal women in the luteal phase: 49 to 346 pg/mL. Postmenopausal women: 10 to 40 pg/mL. Adult men: 10 to 60 pg/mL [5]. These numbers come from immunoassay platforms (Roche Elecsys, Abbott Architect) used by Quest Diagnostics, Labcorp, and hospital systems nationwide.

The Endocrine Society's 2020 position statement on estrogen measurement noted that immunoassay-based estrone values carry a coefficient of variation of 15 to 25% at low concentrations, and recommended liquid chromatography-tandem mass spectrometry (LC-MS/MS) for clinical decisions involving postmenopausal women or men [6]. If your lab used an immunoassay and your E1 is 12 pg/mL, that number could realistically represent anything from 9 to 15 pg/mL. Precision matters when the reference range itself is only 30 pg/mL wide.

The 2023 AACE/ACE guidelines on menopause management acknowledged this limitation: "Reference intervals for estrone derived from population norms do not define therapeutic targets and should not be used in isolation to guide hormone therapy dosing" [7].

Functional Optimal Ranges: A Different Framework

A functional optimal range asks a different question. Instead of "where does 95% of the population fall," it asks "where do patients feel best and carry the lowest measurable risk?" This reframe is borrowed from thyroid medicine, where TSH "normal" of 0.4 to 4.5 mIU/L is far wider than the 1.0 to 2.0 mIU/L range where most patients report symptom resolution [8].

For postmenopausal estrone, the functional optimal zone that many integrative and preventive endocrinologists target is 20 to 35 pg/mL. Below 20, patients commonly report persistent vasomotor symptoms, vaginal dryness, and accelerated bone mineral density loss. Above 35 to 40, the risk-benefit calculation shifts: adipose-driven estrone excess correlates with endometrial hyperplasia risk and may amplify breast cancer signaling through the E1S reservoir pathway [9].

For premenopausal women, the follicular-phase sweet spot is typically 40 to 100 pg/mL, with values above 150 pg/mL in the early follicular phase raising concern for conditions like estrogen dominance or PCOS-related anovulation.

For men on testosterone replacement therapy (TRT), E1 above 40 pg/mL often parallels elevated estradiol and may contribute to gynecomastia or fluid retention. A target of 15 to 35 pg/mL aligns with symptom-free status in most male patients on TRT [10].

One critical distinction: functional ranges are clinician-derived heuristics, not randomized-trial endpoints. They draw from pattern recognition across thousands of patient encounters. No RCT has randomized postmenopausal women to estrone targets of 20 vs. 35 pg/mL and measured outcomes. Use functional ranges as a starting framework, then individualize based on symptoms and downstream metabolite testing (2-OHE1, 4-OHE1, 16α-OHE1).

Why the Gap Between Normal and Optimal Exists

Reference ranges are built from population data that include people who are symptomatic, metabolically unhealthy, or biochemically compensating. A 2017 cross-sectional study in Menopause (N=1,438 postmenopausal women aged 50 to 79) found that 34% of participants with E1 values inside the "normal" range of 10 to 40 pg/mL reported moderate-to-severe hot flashes, and 22% met criteria for osteopenia on DXA [11].

The problem compounds with body composition. Aromatase activity scales with adipose tissue mass. A woman with a BMI of 34 may have an E1 of 38 pg/mL, technically "normal," while a lean woman with a BMI of 21 may sit at 11 pg/mL, also "normal." Their clinical pictures are completely different. The heavier patient may be experiencing estrogen-mediated endometrial stimulation while the leaner patient has symptomatic deficiency. The reference range calls both results acceptable.

Lab assay variability makes the gap worse. A 2021 multicenter comparison published in Clinical Chemistry showed that estrone results for the same pooled serum sample differed by up to 40% across four major immunoassay platforms [12]. LC-MS/MS results clustered within 8% of each other. If you are using estrone to make treatment decisions, the assay method is not optional information.

High Estrone: Clinical Significance and Risk

Elevated estrone in postmenopausal women is not benign. The Women's Health Initiative Observational Study (N=5,998) measured baseline sex steroids and followed participants for a median of 8.6 years. Women in the highest E1 quintile (≥40 pg/mL) had a hazard ratio of 1.47 (95% CI 1.13 to 1.92) for invasive breast cancer compared to those in the lowest quintile [13].

The mechanism is straightforward. Estrone is converted to estrone sulfate, which enters breast ductal cells and is reactivated locally by steroid sulfatase. The resulting intratissue estrogen concentration can be 10 to 50 times higher than what the serum level suggests [3]. This is why aromatase inhibitors like letrozole and anastrozole, which block the conversion of androstenedione to estrone, reduce breast cancer recurrence by 40 to 50% in receptor-positive disease [14].

High E1 also correlates with endometrial pathology. A prospective study of 642 postmenopausal women with abnormal uterine bleeding found that those with E1 above 45 pg/mL had a 3.2-fold higher rate of endometrial hyperplasia on biopsy compared to those below 25 pg/mL [15].

Common drivers of elevated estrone include obesity (BMI ≥30), exogenous estrogen use without adequate progesterone opposition, chronic alcohol intake exceeding 14 drinks per week, and hepatic dysfunction that impairs estrogen conjugation and clearance.

Low Estrone: When Deficiency Causes Symptoms

Estrone below 10 to 15 pg/mL in postmenopausal women often coincides with a clinical picture that standard menopause treatment guidelines already address: refractory vasomotor symptoms, urogenital atrophy, mood instability, and bone loss.

The Study of Women's Health Across the Nation (SWAN) tracked 3,302 women through the menopausal transition for 16 years. Participants whose E1 dropped below the 10th percentile during late perimenopause experienced a 2.1-fold greater annual decline in lumbar spine BMD compared to those in the 50th percentile, even after adjustment for age, BMI, and physical activity [16].

Dr. JoAnn Pinkerton, past president of The North American Menopause Society, has stated: "Estrogen deficiency after menopause is not simply the absence of periods. It is a metabolic state that accelerates cardiovascular aging, bone resorption, and neurocognitive decline when left unaddressed" [17].

Low E1 is especially relevant for lean, physically active postmenopausal women. Without significant adipose reserves, peripheral aromatization is minimal, and total estrogen exposure may be far lower than even the bottom of the reference range. These patients are often overlooked because they "look healthy." Their lab may read 8 pg/mL and get filed as normal because it still appears on the report without a flag (some labs only flag values below 7 pg/mL).

How to Lower Estrone Levels

Reducing estrone centers on decreasing peripheral aromatization and improving hepatic estrogen clearance. The most effective non-pharmacologic intervention is body fat reduction. A 2012 RCT published in the Journal of Clinical Oncology (N=439 overweight postmenopausal women) found that a 12-month diet-and-exercise program producing an average 10.8% weight loss reduced serum E1 by 9.6% and free E1 by 13.4% vs. controls [18].

Other evidence-based strategies:

Limit alcohol to seven or fewer drinks per week. Ethanol upregulates aromatase expression in adipose tissue and impairs hepatic conjugation of estrone [19].

Increase cruciferous vegetable intake (broccoli, Brussels sprouts, kale). These contain indole-3-carbinol (I3C), which shifts estrogen metabolism toward the 2-hydroxylation pathway and away from the proliferative 16α-hydroxylation pathway. A randomized crossover study in Cancer Epidemiology, Biomarkers & Prevention showed that 400 mg/day of I3C increased the 2:16α hydroxyestrone ratio by 47% over 12 weeks [20].

Support hepatic phase II conjugation with adequate dietary fiber (≥25 g/day), which binds conjugated estrogens in the gut and prevents enterohepatic recirculation. B vitamins (B6, B12, folate) and magnesium serve as cofactors for COMT-mediated methylation of catechol estrogens [21].

Pharmacologically, aromatase inhibitors (letrozole 2.5 mg/day, anastrozole 1 mg/day) are indicated for estrogen receptor-positive breast cancer but are sometimes used off-label in men with TRT-related estrogen excess. This use requires monitoring of bone density, lipid panels, and joint symptoms [14].

How to Raise Estrone Levels

Raising estrone is rarely a standalone clinical goal. Because estrone is the weaker estrogen, clinicians typically target estradiol restoration when estrogen replacement is indicated. Oral estradiol (0.5 to 2 mg/day) undergoes extensive first-pass hepatic metabolism and generates significant estrone as a byproduct, resulting in E1:E2 ratios of 3:1 to 5:1 [22]. Transdermal estradiol (patches delivering 0.025 to 0.1 mg/day) bypasses first-pass metabolism and produces E1:E2 ratios closer to 1:1, which more closely mirrors premenopausal physiology [22].

The choice between oral and transdermal routes directly affects the estrone level. If a clinician specifically wants to raise E1 (uncommon), oral estradiol accomplishes this. If the goal is to restore estradiol while keeping E1 from rising disproportionately, transdermal delivery is preferred.

The Endocrine Society's 2015 clinical practice guideline for postmenopausal hormone therapy states: "Transdermal estradiol at doses of 0.025 to 0.05 mg/day provides effective symptom relief with lower thrombotic risk than oral formulations, in part because it avoids the hepatic first-pass effect that increases clotting factor synthesis and raises estrone concentrations" [23].

For patients with very low E1 due to extremely low body fat (athletes, patients recovering from anorexia), restoring body weight and adipose tissue is the physiologic first step. Caloric adequacy and adequate dietary fat intake (≥0.8 g/kg/day) support adrenal androstenedione production, which is the substrate for peripheral aromatization.

The E1:E2 Ratio and What It Tells Your Clinician

Measuring estrone without estradiol is like checking systolic blood pressure without diastolic. The ratio between E1 and E2 carries diagnostic and therapeutic weight.

In premenopausal women, the E1:E2 ratio during the follicular phase is roughly 1:1. After menopause, with estradiol production collapsing and estrone sustained by adipose aromatization, the ratio shifts to 2:1 or higher [24]. A postmenopausal E1:E2 ratio above 4:1 suggests heavy reliance on peripheral conversion with minimal ovarian or exogenous estradiol contribution. This pattern has been associated with increased breast tissue exposure to estrone-derived metabolites.

For women on oral HRT, the ratio often sits between 3:1 and 5:1 due to hepatic conversion. On transdermal HRT, the ratio narrows to 1:1 to 2:1. Clinicians who track this ratio are typically deciding between oral and transdermal delivery routes or adjusting doses to bring the ratio closer to physiologic norms [22].

For men on TRT, an elevated E1:E2 ratio (above 3:1) with symptoms of estrogen excess may suggest that aromatase activity is preferentially producing E1 over E2, or that E2 is being rapidly converted to E1. In these cases, lowering body fat percentage and reassessing testosterone dose are first-line interventions before reaching for an aromatase inhibitor.

Testing Logistics: When, How, and How Often

Order estrone as part of a comprehensive sex-hormone panel that includes estradiol (E2), sex hormone-binding globulin (SHBG), testosterone (total and free), and DHEA-S at minimum. Request LC-MS/MS methodology when available, particularly for postmenopausal women and men whose values will be in the low range where immunoassay imprecision is greatest [6].

Draw fasting, in the morning, before any topical hormone application. For premenopausal women, draw on cycle day 3 to 5 for a follicular-phase baseline. Postmenopausal women and men can draw any day.

Recheck at 8 to 12 weeks after initiating or adjusting hormone therapy. Once stable, annual monitoring is sufficient for most patients. Add more frequent testing if BMI changes significantly (±3 kg/m²), if symptoms recur, or if new medications that affect aromatase or SHBG are introduced (e.g., letrozole, clomiphene, insulin sensitizers).

The 2020 Endocrine Society position statement recommended that clinicians document the assay platform and methodology alongside results: "Clinicians should record whether estrone was measured by immunoassay or LC-MS/MS, as inter-method discordance at postmenopausal concentrations can exceed 35% and alter clinical decisions" [6].